Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QY201 in moderate to severe atopic dermatitis
NCT05525715Phase 2Not yet recruiting
- Sponsor
- E-nitiate
- Start
- Oct 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of qy201 in atopic dermatitis (AD) (10 arms), sponsored by E-nitiate. Primary endpoints: Treatment Emergent Adverse Events and Eczema Area and Severity Index 75% Improvement at Week 12. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
qy201
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05525715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05525715.